Y-mabs Therapeutics Stock News

Y-MAbs Therapeutics, Inc. (YMAB) CEO Claus Møller on Q4 2021 Results - Earnings Call Transcript

Y-mAbs Therapeutics press release (YMAB): FY GAAP EPS of -$1.28 misses by $0.59.Revenue of $34.9M (+68.2% Y/Y) beats by $24.08M.

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the fourth quarter and the full year ended December 31, 2021 and provided recent corporate highlights.

YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -19.72% and 7.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s

NEW YORK, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the year ended December 31, 2021 on Thursday, February 24, 2022, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday, February 25, 2022, at 9 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and President; Dr. Claus Moller, Chief Executive Officer; and Bo Kruse, Chief Financial Officer.

Gainers Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB ) … Full story available on Benzinga.com

Kaival Brands Innovations KAVL +42%. Y-mAbs Therapeutics YMAB +29%

Gainers: Orphazyme ORPH +22%. Y-mAbs Therapeutics YMAB +11%. Oscar Health (OSCR) +9%. Theravance Biopharma TBPH +9%. VistaGen Therapeutics (VTGN) +8%.Losers: ProQR Therapeutics PRQR -72%

Y-mAbs Therapeutics (YMAB) is trading ~9% higher in the pre-market on Friday after the company announced its plans to resubmit the U.S

NEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ: YMAB ) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it recently completed a Pre-Biologics License Application ("pre-BLA") meeting with the U.S. Food and Drug Administration ("FDA") regarding a potential pathway for FDA approval of omburtamab for the treatment of patients with CNS/leptomeningeal metastases from neuroblastoma. The Company expects to resubmit the BLA for omburtamab by the end of the first quarter 2022. A data readout from a single-center clinical study (Study 03-133) of omburtamab conducted at Memorial Sloan Kettering ("MSK"), where 107 evaluable patients with CNS/leptomeningeal metastases from neuroblastoma received up to two doses of radiolabeled omburtamab, showed that patients had a median survival of 50.0 months, with the final median not yet being reached.

Y-mAbs Therapeutics Inc. (NASDAQ:YMAB)s traded shares stood at 1.13 million during the last session, with the companys beta value hitting 1.28. At the close of trading, the stocks price was $7.03, to imply an increase of 1.59% or $0.11 in intraday trading. The YMAB shares 52-week high remains $50.70, putting it -621.19% down since that Y-mAbs Therapeutics Inc. (NASDAQ: YMAB) Has Succeeded In Gaining Momentum In 2022, The Stock Is Down -56.63% YTD Read More »

YmAbs Therapeutics, Inc. (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further p

Y-Mabs Therapeutics Inc (YMAB) shares closed 2.2% lower than its previous 52 week low, giving the company a market cap of $548M. The stock is currently down 22.5% year-to-date, down 74.3% over the past 12 months, and down 47.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.7%. Trading Activity Trading volume this week was 22.8% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 7.8% lower than its 5-day moving average, 22.3% lower than its 20-day moving average, and 45.7% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 542.3% The company's stock price performance over the past 12 months lags the peer average by 142.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Y-Mabs Therapeutics Inc (YMAB) shares closed today at 0.7% above its 52 week low of $13.94, giving the company a market cap of $612M. The stock is currently down 13.4% year-to-date, down 72.7% over the past 12 months, and down 41.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 4.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 741.5% The company's stock price performance over the past 12 months lags the peer average by 141.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.